Rhizen Pharmaceuticals Archives

Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China

La Chaux-de-Fonds, Switzerland and Shanghai, China, Oct. 12 (Korea Bizwire) — Rhizen Pharmaceuticals S. A. (Rhizen), a Switzerland-based privately held clinical-stage biopharmaceutical company, and Curon Biopharmaceutical Limited (Curon), a clinical-stage innovative biopharmaceutical company with facility in Shanghai announced today that they have entered into an exclusive licensing agreement for the development and commercialization of Tenalisib, [...]

$Rhizen Pharmaceuticals S.A. Announces Publication of Clinical Data from the Phase I/Ib study of Tenalisib (RP6530) in Patients with Relapsed/Refractory T-Cell Lymphoma (TCL)$

Rhizen Pharmaceuticals S.A. Announces Publication of Clinical Data from the Phase I/Ib study of Tenalisib (RP6530) in Patients with Relapsed/Refractory T-Cell Lymphoma (TCL)

La Chaux-de-Fonds, Switzerland, Sept. 24 (Korea Bizwire) — Rhizen Pharmaceuticals S.A. today announced the publication of the results from the Phase I/Ib study of Tenalisib (RP6530), the company’s novel next generation dual PI3K δ/γ inhibitor, in the journal Cancers. — Single-agent Tenalisib was well tolerated with a good overall response rate (ORR) in both peripheral and cutaneous T-cell [...]